SEC Form 4 · accession 0000886163-17-000099
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew W Foehr
Officer — President and COO
Period of report
Aug 9, 2017
Accepted (ET)
Aug 10, 2017 · 6:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 9, 2017 | M | 6,100 | $9.97 | A | 101,020 | D | |
| Common StockF1 | Aug 9, 2017 | S | 6,100 | $127.5121 | D | 94,920 | D | |
| Common Stock | Aug 9, 2017 | M | 850 | $9.97 | A | 95,770 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $9.97 | Aug 9, 2017 | M | 6,100 | D | — | Apr 18, 2021 | Common Stock | 6,100 | 43,935 | D |
| Employee Stock Option (right to buy)F2 | $9.97 | Aug 9, 2017 | M | 850 | D | — | Apr 18, 2021 | Common Stock | 850 | 43,085 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.4774 to $127.8374, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.